<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386761</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-06001AA1-08</org_study_id>
    <nct_id>NCT02386761</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001</brief_title>
  <acronym>CHF6001Ext</acronym>
  <official_title>A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doseS in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I randomised, double-blind, placebo-controlled study of single and repeated ascending
      doses in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of
      inhaled chf 6001.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of single and repeated ascending doses of CHF 6001 in
      healthy volunteers and to investigate the pharmacokinetic (PK) profile of CHF 6001 and its
      metabolites CHF 5956 and CHF 6095.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>0-14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg
Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg
Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.
In case the actual doses are modified, the number of inhalations will be adapted accordingly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo
Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo
Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo
Duration 14 days b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Ascending Dose (SAD)</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <other_name>CHF6001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple Ascending Dose (MAD)</intervention_name>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <other_name>CHF6001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion

          -  Subject's written informed consent obtained prior to any study-related procedure

          -  Male and female Caucasian healthy volunteers aged 18-55 years inclusive

          -  Vital signs:Subjects aged 18-45: Diastolic BP 40-90, Systolic BP 90-140 Subjects aged
             45-55: Diastolic BP 40-90, Systolic BP 90-150 (as mean of three measures performed
             after at least 5 minutes of resting); checked at screening visit and Day -1

          -  12-lead digitised Electrocardiogram (12-lead ECG) considered as normal (40≤Heart
             rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms
             for females) checked at screening visit and Day -1

          -  Lung function measurements within normal limits: FEV1 &gt; 80% of predicted normal value
             (according to the Global Lung Function Initiative, ERS Task Force Lung Function
             Reference Values (1,2) ) and FEV1/FVC ratio &gt; 0.70

        Main Exclusion:

          -  Pregnant or lactating women

          -  Clinically significant cardiac abnormalities

          -  Any clinically relevant abnormal laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>UK</state>
        <zip>NG116JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

